FDA Vote on Roxadustat in Anemia of Chronic Kidney Disease

The FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has voted 13 to 1 that the benefit-risk profile of roxadustat does not support approval for the treatment of anemia in chronic kidney disease (CKD) in non-dialysis dependent (NDD) adult patients, and 12 to 2 that the benefit-risk profile of roxadustat does not support approval for the treatment of anemia in CKD in dialysis-dependent (DD) adult patients.

The FDA will consider the vote, independent opinions and recommendations from experts as it reviews the new drug application (NDA) and is not bound by the Committee’s recommendation.

The safety and efficacy of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, have been demonstrated in the Phase III program including more than 8,000 patients and published in five peer-reviewed journal articles.

Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said, “New solutions are needed for the six million people in the US affected by anemia of chronic kidney disease. Although we are disappointed by this outcome, we will continue to work closely with our partner FibroGen and the FDA to determine the path forward for roxadustat.”

Earlier this year, the FDA confirmed it would convene a meeting of the CRDAC to review the NDA for roxadustat and requested further clarifying analyses of clinical data to support the assessment. The FDA has not announced when it will make its final decision for the roxadustat NDA.

Roxadustat is approved in a number of countries, including China, Japan, Chile and South Korea for the treatment of anemia in CKD in NDD and DD adult patients. It is under regulatory review in other jurisdictions, including in the European Union, where it has recently received a positive CHMP opinion.